Entropy Neurodynamics wins ethics approval for 72-patient TRP-8803 basket trial

• Entropy Neurodynamics secured Human Research Ethics Committee clearance to start a Phase 1b/2a basket trial of TRP-8803, an IV psilocin therapy.
• The open-label study targets 72 patients across eight indications to speed indication selection and support commercialization planning.
• Swinburne University signed a clinical trial research agreement to help run the program; first dosing is expected later this quarter.
• Budget set at about AUD 3.2 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entropy Neurodynamics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN18483) on August 04, 2026, and is solely responsible for the information contained therein.